Braf V600e Mutant Pediatric Low Grade Glioma Therapeutics
1. Ojemda patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8293752 | DAY ONE BIOPHARMS | Compounds useful as Raf kinase inhibitors |
Aug, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10426782 | DAY ONE BIOPHARMS | Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation |
Jun, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 23, 2029 |
| Orphan Drug Exclusivity(ODE-478) | Apr 23, 2031 |
Drugs and Companies using TOVORAFENIB ingredient
NCE-1 date: 23 April, 2028
Market Authorisation Date: 23 April, 2024
Dosage: TABLET; FOR SUSPENSION
More Information on Dosage
OJEMDA family patents
